NASDAQ:NVCT

Track all markets on TradingView - Prices are not updated in real time
Nuvectis Pharma (NVCT) Gains in Premarket as Analysts Reaffirm Confidence

Nuvectis Pharma (NASDAQ: NVCT) moved higher in premarket trading on Monday after receiving fresh analyst support, extending positive sentiment toward the clinical-stage oncology company.

Shares rose 1.4% in premarket trading after closing 0.3% higher on Thursday. Roth MKM reiterated its Buy rating on Nuvectis, while UBS initiated coverage with a $33.00 price target.

The analyst actions underscore continued confidence in Nuvectis' long-term potential as it advances its pipeline of targeted cancer therapies. The positive outlook reflects optimism surrounding the company's clinical development strategy and future value creation opportunities.

Nuvectis is focused on developing precision oncology treatments targeting difficult-to-treat cancers, with investors closely monitoring upcoming clinical milestones that could serve as important catalysts.

The combination of a reiterated Buy rating from Roth MKM and a new price target from UBS helped support shares in premarket trading, as investors welcomed additional institutional coverage despite the inherent risks associated with clinical-stage biotechnology companies.
💬 🔗
Author
European Investor 07-06-26
Nuvectis Pharma Advances NXP900 Clinical Program; Reports Q3 2025 Results

Nuvectis Pharma, Inc. (NASDAQ: NVCT) reported third-quarter 2025 financial results and provided updates on the clinical progress of its lead candidate, NXP900. The company has initiated its Phase 1b single-agent study, targeting patients with advanced cancers defined by specific molecular and histological profiles, and plans to launch the combination therapy phase by the end of 2025.

The Phase 1a dose escalation and drug-drug interaction studies were successfully completed, demonstrating robust pharmacodynamic responses and supporting once-daily oral dosing and combination potential. Data presented at the AACR-NCI-EORTC 2025 conference further reinforced NXP900’s biomarker-based patient selection approach.

CEO Ron Bentsur emphasized that the company’s focus is now on advancing NXP900 through Phase 1b, exploring its potential to overcome resistance when combined with established cancer therapies.

Financially, Nuvectis reported a net loss of $7.5 million for Q3 2025, compared with $4.2 million a year earlier, mainly due to a $2 million milestone payment and $0.7 million in drug interaction study costs. Research and development expenses rose to $5.8 million from $2.8 million, while general and administrative costs increased to $2 million from $1.5 million.

Cash and equivalents stood at $35.4 million as of September 30, 2025, up from $18.5 million at year-end 2024, primarily driven by a February public offering and ATM facility proceeds. The company projects its cash runway will sustain operations into the third quarter of 2027.
💬 🔗
Author
WS Investor 11-04-25